Strensiq (Asfotase Alfa)
Brand Names: Strensiq
Methodology & AI Transparency ⓘ
Strensiq (Asfotase Alfa) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Strensiq (Asfotase Alfa) represents a prescription brand-name tissue-nonspecific alkaline phosphatase entry registered by Alexion Pharmaceuticals, Inc.
- 2 Real-world patient consensus: Branded tissue-nonspecific alkaline phosphatase presentation of Asfotase Alfa (Alexion Pharmaceuticals, Inc.); generic reference: /meds/asfotase-alfa.
- 3 Typical cash cost range: 30-day cash pricing ranges from $30.82 discount cash to $81.67 walk-in retail (NADAC $0.3100/unit).
- 4 Top reported side effects / signs: Most commonly reported Strensiq (Asfotase Alfa) tolerability events: nausea (7.9%), headache (6.8%), dizziness (6%).
Ask our AI Specialists anything about Strensiq (Asfotase Alfa)
Strensiq (Asfotase Alfa) Mechanism, CYP450 Pathways & DailyMed Monograph
Strensiq (Asfotase Alfa) represents a prescription brand-name tissue-nonspecific alkaline phosphatase entry registered by Alexion Pharmaceuticals, Inc. with package codes 25682-010, 25682-013. Reviewed against 2025-12-12 FDA SPL standards (40 mg/mL Solution; 18 mg/.45mL Solution), clinical deployment addresses 1 Indications and usage strensiq: ® is indicated for the treatment of patients with perinatal/infantile- and.
Strensiq achieves therapeutic action via Asfotase Alfa, engaging tissue-nonspecific alkaline phosphatase physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 40 mg/mL Solution; 18 mg/.45mL Solution (registered by Alexion Pharmaceuticals, Inc., NDC 25682-010, 25682-013), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Strensiq ($81.67 retail) with generic Asfotase Alfa ($30.82 low cash).
Following administration (40 mg/mL Solution), Strensiq (Asfotase Alfa) achieves Oral fraction absorbed ranges from 48% to 60% (Strensiq (Asfotase Alfa) 40) bioavailability and oral tmax achieved within 2 to 4 hours following strensiq (asfotase alfa) ingestion onset, governed by a Mean elimination half-life of 7 to 19 hours across adult Strensiq (Asfotase Alfa) dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of strensiq (asfotase alfa).
Before initiating Strensiq (Asfotase Alfa) at 40 mg/mL Solution, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to strensiq (asfotase alfa) (ndc 25682-010); severe baseline organ impairment where asfotase alfa accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (7.9% of reports), headache (6.8% of reports), dizziness (6% of reports).
Reconcile eGFR-adjusted medications before escalating Strensiq (Asfotase Alfa) in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Strensiq (Asfotase Alfa) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Strensiq (Asfotase Alfa) (NDC 25682-010)
- Severe baseline organ impairment where Asfotase Alfa accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (20 Reports)
Strensiq (Asfotase Alfa) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Strensiq (Asfotase Alfa))
Human clinical trial evidence for Strensiq (Asfotase Alfa) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Strensiq (Asfotase Alfa) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.3100/unit (~$9.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $81.67 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $30.82 / mo | View logs ↓ |
Strensiq (Asfotase Alfa) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Strensiq (Asfotase Alfa) RxNorm Concept ID | 1720268 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $81.67 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $30.82 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Strensiq (Asfotase Alfa) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Strensiq (Asfotase Alfa) integrating DailyMed SPL (2025-12-12), CMS NADAC ($0.3100/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Strensiq (Asfotase Alfa) community threads and patient logs by age, biological sex, dosage, and treatment duration.